Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Lung Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Neoplasm, Residual 2NSCLC 2Leukemia, Myeloid, Chronic-Phase 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms, Second Primary 1Neoplasms by Site 1Lung Diseases 1Liver Neoplasms 1Leukemia, Biphenotypic, Acute 1Leukemia 1Gastro Intestinal Stromal Tumor 1Endometrial Neoplasms 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 254fludarabine phosphate 165Cytarabine 160Methotrexate 128Busulfan 115Filgrastim 111fludarabine 102Peripheral Blood Stem Cell Transplantation 96Rituximab 94Antilymphocyte Serum 83Etoposide 81Cyclosporine 75Tacrolimus 74Mycophenolic Acid 73Whole-Body Irradiation 72Radiotherapy 70Melphalan 66Vincristine 55Dexamethasone 54Granulocyte Colony-Stimulating Factor 50Methylprednisolone 48Azacitidine 44Alemtuzumab 42Imatinib Mesylate 41Clofarabine 41sargramostim 40Idarubicin 36Daunorubicin 36Cord Blood Stem Cell Transplantation 36Thiotepa 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia × Tyrosine Kinase Inhibitors × Clear all
NCT01460498 2020-03-05

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

M.D. Anderson Cancer Center

Phase 1 Completed
3 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡